Results for tag: "Benign Prostatic Hyperplasia Drug"

Benign Prostatic Hyperplasia (BPH) is a condition that affects the prostate gland in men. It is characterized by an enlarged prostate, which can cause urinary symptoms such as difficulty starting or stopping the flow of urine, a weak or interrupted urine stream, and a feeling of incomplete bladder emptying. BPH is not cancerous, but it can lead to an increased risk of developing prostate cancer. The BPH drug market is composed of a variety of medications used to treat the symptoms of BPH. These medications include alpha-blockers, 5-alpha reductase inhibitors, and anticholinergics. Alpha-blockers work by relaxing the muscles of the bladder neck and prostate, allowing for improved urine flow. 5-alpha reductase inhibitors reduce the size of the prostate, while anticholinergics reduce bladder contractions. The BPH drug market is a subset of the larger prostate cancer drug market. Prostate cancer drugs are used to treat prostate cancer, which is the second most common cancer in men. These drugs include hormone therapy, chemotherapy, and immunotherapy. Some companies in the BPH drug market include Allergan, Astellas Pharma, and GlaxoSmithKline. Show Less Read more